Recursion Pharmaceuticals Inc Clas (RXRX)
Cost of Revenue
$80.45M
TTM · Period ending: · USD
RXRX Cost of Revenue
Latest reported$80.45Mperiod ending
Latest reported$80.45Mperiod ending
RXRX TTM Cost of Revenue ($0.00 → $80.45M)
TTM cost of revenue
High-resolution chart · PNG
RXRX cost of revenue history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 80,450,000 | |
| 89,120,000 | |
| 98,459,000 | |
| 84,377,000 | |
| 66,863,000 | |
| 55,901,000 | |
| 45,238,000 | |
| 42,325,000 | |
| 41,123,000 | |
| 41,306,000 | |
| 42,588,000 | |
| 43,547,000 | |
| 48,079,000 | |
| 52,924,000 | |
| 48,275,000 | |
| 37,435,000 | |
| 22,026,000 | |
| 7,799,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |